Bosentan

Major

Bosentan Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Bosentan Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Bosentan Atogepant Qulipta Reduced atogepant exposure Details Bosentan Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Bosentan Azathioprine Azasan An increased risk of hepatotoxicity Details Bosentan Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Bosentan Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Bosentan Amlodipine Amvaz® Reduced amLODIPine exposure Details Bosentan Axitinib Inlyta Reduced axitinib exposure Details Bosentan Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Bosentan Brigatinib Alunbrig Decreased brigatinib exposure and efficacy Details Bosentan Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Bosentan Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Bosentan Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Bosentan Cobimetinib Cotellic Decreased cobimetinib plasma concentrations Details Bosentan Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Bosentan Deflazacort Emflaza Decreased exposure to active metabolite of deflazacort Details Bosentan Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details Bosentan Doxorubicin Adriamycin Reduced DOXOrubicin exposure Details Bosentan Elacestrant Orserdu Reduced elacestrant exposure and reduced efficacy of elacestrant Details Bosentan Encorafenib Braftovi Reduced encorafenib exposure, reduced efficacy of encorafenib, increased bosentan exposure and increased risk of bosentan-related... Details Bosentan Entrectinib Rozlytrek Reduced entrectinib exposure and reduced efficacy of entrectinib Details Bosentan Erdafitinib Balversa Reduced erdafitinib exposure Details Bosentan Estradiol Delestrogen Reduced hormonal contraceptive exposure, reduced efficacy of hormonal contraceptive and an increased risk of breakthrough bleeding... Details Bosentan Estradiol Topical Divigel Reduced hormonal contraceptive exposure, reduced efficacy of hormonal contraceptive and an increased risk of breakthrough bleeding... Details Bosentan Estradiol Transdermal Patch Alora® Reduced hormonal contraceptive exposure, reduced efficacy of hormonal contraceptive and an increased risk of breakthrough bleeding... Details Bosentan Fentanyl Transdermal Patch Duragesic® Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Bosentan Finerenone Kerendia Reduced finerenone exposure and reduced efficacy of finerenone Details Bosentan Glasdegib Daurismo Reduced glasdegib exposure Details Bosentan Ibrexafungerp Brexafemme Decreased ibrexafungerp plasma concentrations Details Bosentan Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Bosentan Ketoconazole Topical Extina® Foam Increased bosentan exposure Details Bosentan Lefamulin Xenleta Reduced lefamulin exposure and reduced efficacy of lefamulin Details Bosentan Leflunomide Arava Increased exposure of OATP1B1/1B3 substrate Details Bosentan Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Bosentan Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Bosentan Leniolisib Joenja Increased bosentan exposure, reduced leniolisib exposure and reduced efficacy of leniolisib Details Bosentan Letermovir Injection Prevymis Increased bosentan exposure, reduced letermovir exposure and reduced efficacy of letermovir Details Bosentan Levonorgestrel After banger Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Bosentan Levonorgestrel Intrauterine System Kyleena Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details